Evidence map›Paper›PMID 42035252›Full record

ArticleChemMedChem2026

In Vitro Evaluation of PARP1 Inhibitor Olaparib-Cyanine Dye Conjugate for the Treatment of Glioblastoma.

Carina Dumo, Faheem, Peter J Choi, Nicholas J Pederson, Yuge Liu, Mike Dragunow, Thomas I-H Park, Katharine L Diehl, Jiney Jose

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carina DumoAuckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
FaheemMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.ORCID 0000-0002-2306-3050
Peter J ChoiAuckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
Nicholas J PedersonDepartment of Medicinal Chemistry, University of Utah, Salt Lake City, Utah, USA.
Yuge LiuAuckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
Mike DragunowDepartment of Pharmacology & The Centre for Brain Research, University of Auckland, Auckland, New Zealand.
Thomas I-H ParkDepartment of Pharmacology & The Centre for Brain Research, University of Auckland, Auckland, New Zealand.
Katharine L DiehlDepartment of Medicinal Chemistry, University of Utah, Salt Lake City, Utah, USA.
Jiney JoseAuckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand.ORCID 0000-0002-1325-438X

Funding

Eavesdropping on the conversation between chromatin and metabolismR35GM143080 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI DIEHL, KATHARINE · 2021 to 2025
$1.9M
Cure Kids 5500Neurological Foundation of New Zealand 2127 PRGNIGMS NIH HHS R35 GM143080NIH HHS R35GM143080
6 · The paper itself

Abstract

Inhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer. This approach, although very attractive, has not been feasible for treating brain tumours due to the stringent structural features necessary for pharmaceutical agents to cross the blood-brain barrier (BBB). This study presents the proof of concept in vitro cellular activity of PARP1 (Poly(ADP-ribose) polymerase 1) enzyme inhibitor olaparib conjugated with a known BBB-crossing heptamethine cyanine dye. We also present evidence for cellular uptake and PARP1 inhibition by the conjugate, which contributes to the observed improvement in potency.

Indexed as

Antineoplastic AgentsCarbocyaninesGlioblastomaPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsBrain NeoplasmsCell Line, TumorDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructurePoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesStructure-Activity RelationshipAntineoplastic AgentsCarbocyaninesolaparibPARP1 protein, humanPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerasesglioblastomaheptamethine cyanine dyesolaparibPARP inhibition

Identifiers

PMID42035252
PMCPMC13110365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.